Bridging intravenous thrombolysis in patients with atrial fibrillation.

Publication

Bridging intravenous thrombolysis in patients with atrial fibrillation.

Journal Paper/Review - Aug 3, 2022

Mujanovic Adnan, Kurmann Christoph C, Dobrocky Tomas, Olivé-Gadea Marta, Maegerlein Christian, Pierot Laurent, Mendes Pereira Vitor, Costalat Vincent, Psychogios Marios-Nikos, Michel Patrik, Beyeler Morin, Piechowiak Eike Immo I, Seiffge David Julian, Mordasini Pasquale, Arnold Marcel, Gralla Jan, Fischer Urs, Kaesmacher Johannes, Meinel Thomas Raphael, BEYOND-SWIFT Investigators

Citation

Mujanovic A, Kurmann C, Dobrocky T, Olivé-Gadea M, Maegerlein C, Pierot L, Mendes Pereira V, Costalat V, Psychogios M, Michel P, Beyeler M, Piechowiak E, Seiffge D, Mordasini P, Arnold M, Gralla J, Fischer U, Kaesmacher J, Meinel T, BEYOND-SWIFT Investigators. Bridging intravenous thrombolysis in patients with atrial fibrillation. Front Neurol 2022; 13:945338.

Type

Journal Paper/Review (English)

Journal

Front Neurol 2022; 13

Publication Date

Aug 3, 2022

Issn Print

1664-2295

Pages

945338

Brief description/objective

40% of acute ischemic stroke patients treated by mechanical thrombectomy (MT) have a clinical history of atrial fibrillation (AF). The safety of bridging intravenous thrombolysis (IVT) (MT + IVT) is currently being discussed. We aimed to analyze the interaction between oral anticoagulation (OAC) status or AF with bridging IVT, regarding the occurrence of symptomatic intracranial hemorrhage (sICH) and functional outcome.